Literature DB >> 10340177

Nitric oxide in the pathogenesis of sepsis.

S Symeonides1, R A Balk.   

Abstract

In sepsis and septic shock, inflammatory mediators result in the production of increased concentrations of nitric oxide (NO) from the enzymatic breakdown of the amino acid L-arginine. The increased amounts of NO are responsible for changes in vasomotor tone, decreased vasopressor responsiveness, and decreased myocardial function, characteristic of septic insult. Therapeutic strategies designed to reduce the concentration of NO by inhibiting the action of the nitric oxide synthase enzyme, or by scavenging the excess NO, offer the potential to treat directly the vasomotor abnormalities and myocardial depression seen in sepsis and other inflammatory states. This article reviews the biology of NO in sepsis and discusses strategies for neutralization of the increased NO production, in the setting of severe sepsis and septic shock.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340177     DOI: 10.1016/s0891-5520(05)70085-4

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  16 in total

1.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

Review 2.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

4.  Na+ - and Cl- -coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B(0,+).

Authors:  T Hatanaka; T Nakanishi; W Huang; F H Leibach; P D Prasad; V Ganapathy; M E Ganapathy
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

5.  Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil.

Authors:  Amadu E Juliana; Filomena C B Abbad
Journal:  Eur J Pediatr       Date:  2005-07-13       Impact factor: 3.183

6.  Gamma interferon prevents the inhibitory effects of oxidative stress on host responses to Escherichia coli infection.

Authors:  M J Parmely; F Wang; D Wright
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 7.  Methylene blue for distributive shock: a potential new use of an old antidote.

Authors:  David H Jang; Lewis S Nelson; Robert S Hoffman
Journal:  J Med Toxicol       Date:  2013-09

8.  CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis.

Authors:  M Hersberger; S Bonhoeffer; S K Rampini; M Opravil; J Marti-Jaun; A Telenti; E Hänseler; B Ledergerber; R F Speck
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 9.  Sepsis 2019: What Surgeons Need to Know.

Authors:  Vanessa P Ho; Haytham Kaafarani; Rishi Rattan; Nicholas Namias; Heather Evans; Tanya L Zakrison
Journal:  Surg Infect (Larchmt)       Date:  2019-11-22       Impact factor: 2.150

10.  Isotopic study of L-Arginine kinetics in the lung during pseudomonas sepsis in an ovine model.

Authors:  Hongzhi Xu; Davin Watson; Yong-Ming Yu; Daniel L Traber; Stefani Fischer; Joan Nichols; Donald Deyo; Lillian L Traber; Joaquin Cortiella
Journal:  Int J Burns Trauma       Date:  2014-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.